Feasibility of MASK-air® use in allergic rhinitis patients receiving immunotherapy and the effect on quality of life
Allergologia et Immunopathologia · 2025
DOI: 10.15586/aei.v53i3.1208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergologia et Immunopathologia, 2025. Verfasst von Özge Kama Başci und 3 weiteren Autor:innen. Beteiligte Einrichtung: Balikesir University, Faculty of Medicine, Department of Internal Medicine, Bigadiç Caddesi, Balıkesir, Türkiye; ozgee.kama@gmail.com. Hauptthemen laut MEDLINE: Quality of Life, Rhinitis, Allergic, Desensitization, Immunologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
The aim of MASK-air® application is to enhance awareness of allergic rhinitis (AR) and its complications, thereby reducing the risk of developing asthma.
Objective
The aims of this study were to evaluate the impact of MASK-air® on the quality of life (QoL) and symptomatology of AR patients undergoing allergen immunotherapy (AIT). The study also evaluated patient satisfaction with the application. Materials and Methods: A prospective cross-sectional study was conducted between August and November 2019 at a tertiary Allergy and Immunology center involving patients receiving AIT. Participants were instructed on accessing and utilizing MASK-air® daily through face-to-face interviews. Concurrently, the Score for Allergic Rhinitis (SFAR) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were administered alongside MASK-air® Visual Analog Scale (VAS) scores. After 6 months, RQLQ scores were reassessed and a satisfaction survey was conducted.
Results
This study comprised 96 patients. Significant correlations were observed among SFAR, RQLQ, and VAS scores. After 6 months of MASK-air® usage, improvements in QoL and symptom reduction were evident. Notably, participants who consistently used MASK-air® demonstrated significant reductions in activity limitations and hay fever scores compared to irregular users (p = 0.05 and p = 0.02, respectively). Additionally, participants under 40 years of age and those with higher education levels exhibited a greater inclination toward online monitoring via the application. Overall, participants found MASK-air® practical, citing various advantages and disadvantages.
Conclusion
MASK-air® serves as a valuable tool for physicians in managing treatment and is associated with validated, reliable scales. Its use was linked to enhanced QoL and symptom reduction among participants, irrespective of treatment duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Balikesir University, Faculty of Medicine, Department of Internal Medicine, Bigadiç Caddesi, Balıkesir, Türkiye; ozgee.kama@gmail.com.
- Manisa Celal Bayar University, Faculty of Medicine, Department of Pulmonology, Manisa, Türkiye.
- Denizli Pamukkale District Health Directorate, Department of Public Health, Denizli, Türkiye.
- Manisa Celal Bayar University, Faculty of Medicine, Department of Internal Medicine, Division of Immunology and Allergy, Manisa, Türkiye.
Zitieren
APA
Başci, Ö. K., Yorgancioglu, A., Gunes, S., & Kirmaz, C. (2025). Feasibility of MASK-air® use in allergic rhinitis patients receiving immunotherapy and the effect on quality of life. Allergologia et Immunopathologia. https://doi.org/10.15586/aei.v53i3.1208
Vancouver
Başci ÖK, Yorgancioglu A, Gunes S, Kirmaz C. Feasibility of MASK-air® use in allergic rhinitis patients receiving immunotherapy and the effect on quality of life. Allergologia et Immunopathologia. 2025. doi:10.15586/aei.v53i3.1208
BibTeX
@article{Baci2025,
author = {Başci, Özge Kama and Yorgancioglu, Arzu and Gunes, Soner and Kirmaz, Cengiz},
title = {Feasibility of MASK-air® use in allergic rhinitis patients receiving immunotherapy and the effect on quality of life},
journal = {Allergologia et Immunopathologia},
year = {2025},
doi = {10.15586/aei.v53i3.1208}
}
EUVIMED